Drug
Nebido
Nebido is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_4
2
67%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 4Post-market surveillance
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 42 (66.7%)
N/A1 (33.3%)
Trials by Status
completed267%
withdrawn133%
Recent Activity
0 active trials
Showing 3 of 3
completednot_applicable
Pubertal Replacement In Boys Study Nebido and Testoviron Depot Treatment
NCT05417035
completedphase_4
Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina
NCT00131183
withdrawnphase_4
Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks
NCT00710827
Clinical Trials (3)
Showing 3 of 3 trials
NCT05417035Not Applicable
Pubertal Replacement In Boys Study Nebido and Testoviron Depot Treatment
NCT00131183Phase 4
Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina
NCT00710827Phase 4
Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3